| Previous close | 0.1500 |
| Open | 0.1300 |
| Bid | 0.1100 |
| Ask | 0.2200 |
| Strike | 110.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.1300 - 0.1300 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksAstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.
ZacksWhy Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ZacksPharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.
© 2024 Yahoo. All rights reserved.